[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Akeno et al., 2017 - Google Patents

TRP53 mutants drive neuroendocrine lung cancer through loss-of-function mechanisms with gain-of-function effects on chemotherapy response

Akeno et al., 2017

View HTML
Document ID
2741305565708909199
Author
Akeno N
Reece A
Callahan M
Miller A
Kim R
He D
Lane A
Moulton J
Wikenheiser-Brokamp K
Publication year
Publication venue
Molecular cancer therapeutics

External Links

Snippet

Lung cancer is the leading cause of cancer-related deaths with small-cell lung cancer (SCLC) as the most aggressive subtype. Preferential occurrence of TP53 missense mutations rather than loss implicates a selective advantage for TP53-mutant expression in …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Similar Documents

Publication Publication Date Title
Onitsuka et al. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status
Nowak et al. MYC drives Pten/Trp53-deficient proliferation and metastasis due to IL6 secretion and AKT suppression via PHLPP2
Samuels et al. Oncogenic PI3K and its role in cancer
Carter et al. Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma
Elkabets et al. AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas
Klemke et al. Hsp90-stabilized MIF supports tumor progression via macrophage recruitment and angiogenesis in colorectal cancer
Okayama et al. NOS2 enhances KRAS‐induced lung carcinogenesis, inflammation and microRNA‐21 expression
Furic et al. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression
Bric et al. Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model
Cataisson et al. IL-1R–MyD88 signaling in keratinocyte transformation and carcinogenesis
Tsuda et al. The BRG1/SOX9 axis is critical for acinar cell–derived pancreatic tumorigenesis
Endersby et al. Nonredundant functions for Akt isoforms in astrocyte growth and gliomagenesis in an orthotopic transplantation model
Yang et al. Lower expression level of IL-33 is associated with poor prognosis of pulmonary adenocarcinoma
Hong et al. Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition
Liu et al. Mutant SF3B1 promotes AKT-and NF-κB–driven mammary tumorigenesis
Xu et al. NSCLC driven by DDR2 mutation is sensitive to dasatinib and JQ1 combination therapy
Akeno et al. TRP53 mutants drive neuroendocrine lung cancer through loss-of-function mechanisms with gain-of-function effects on chemotherapy response
Liu et al. Re-expression of AKAP12 inhibits progression and metastasis potential of colorectal carcinoma in vivo and in vitro
Smith et al. An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis
Wang et al. Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma
Francica et al. Depletion of FOXM1 via MET targeting underlies establishment of a DNA damage–Induced senescence program in gastric cancer
Ruiz et al. JunD, not c-Jun, is the AP-1 transcription factor required for Ras-induced lung cancer
Nokin et al. Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma
Costa‐Machado et al. Sirt1 protects from K‐Ras‐driven lung carcinogenesis
Yin et al. Relationships between chromosome 7 gain, MET gene copy number increase and MET protein overexpression in Chinese papillary renal cell carcinoma patients